Department of Medical Sciences and Public Health, University of Cagliari, SS 554, 09042, Monserrato, CA, Italy.
Rheumatology Unit, Azienda Ospedaliero-Universitaria of Cagliari, Monserrato, Italy.
Arthritis Res Ther. 2022 Nov 17;24(1):253. doi: 10.1186/s13075-022-02947-y.
This study aimed to investigate the trajectory of damage accrual, associated factors, and impact on health-related quality of life (HR-QoL) in a multicenter cohort of patients with Behçet's syndrome (BS) over 2 years of follow-up.
Patients recruited in the BS Overall Damage Index (BODI) validation study were prospectively monitored for 2 years and assessed for damage accrual, defined as an increase ≥1 in the BODI score, and HR-QoL was evaluated by the SF-36 questionnaire. Logistic and multiple linear regression models were built to determine factors associated with damage accrual and impairment in the different SF-36 domains.
During follow-up, 36 out of 189 (19.0%) patients had an increase ≥1 in the BODI score with a mean (SD) difference of 1.7 (0.8) (p <0.001). The incidence rate of damage accrual was stable over time, regardless of the disease duration. Out of 61 new BODI items, 25 (41.0%) were considered related to glucocorticoid (GC) use. In multivariate analysis, duration of GC therapy (OR per 1-year 1.15, 95% CI 1.07-1.23; p <0.001) and occurrence of ≥1 disease relapse (OR 3.15, 95% CI 1.09-9.12; p 0.038) were identified as predictors of damage accrual, whereas the use of immunosuppressants showed a protective effect (OR 0.20, 95% CI 0.08-0.54, p<0.001). Damage accrual was independently associated with the impairment of different physical domains and, to a greater extent, in emotional domains of the SF-36 questionnaire. Female sex, higher disease activity, and fibromyalgia were also significantly associated with impairment in HR-QoL.
In BS, organ damage accrues over time, also in long-standing disease, resulting in an impairment of the perceived physical and mental health. Adequate immunosuppressive treatment, preventing disease flares and minimizing exposure to GCs have a crucial role in lowering the risk of damage accrual.
本研究旨在探讨在贝切特综合征(BS)多中心队列中,经过 2 年的随访,损害累积的轨迹、相关因素及其对健康相关生活质量(HR-QoL)的影响。
在 BS 整体损害指数(BODI)验证研究中招募的患者进行了为期 2 年的前瞻性监测,并评估了损害累积情况,定义为 BODI 评分增加≥1 分,HR-QoL 通过 SF-36 问卷进行评估。构建逻辑回归和多元线性回归模型,以确定与损害累积和不同 SF-36 领域损害相关的因素。
在随访期间,189 名患者中有 36 名(19.0%)BODI 评分增加≥1 分,平均(SD)差值为 1.7(0.8)(p<0.001)。损害累积的发生率随时间稳定,与疾病持续时间无关。在 61 项新的 BODI 项目中,25 项(41.0%)与糖皮质激素(GC)使用有关。在多变量分析中,GC 治疗持续时间(每 1 年增加 1.15 的比值比(95%CI 1.07-1.23);p<0.001)和≥1 次疾病复发(比值比 3.15,95%CI 1.09-9.12;p=0.038)被确定为损害累积的预测因素,而免疫抑制剂的使用则显示出保护作用(比值比 0.20,95%CI 0.08-0.54,p<0.001)。损害累积与 SF-36 问卷不同身体领域的损害以及更广泛的情感领域的损害独立相关。女性、更高的疾病活动度和纤维肌痛也与 HR-QoL 的损害显著相关。
在 BS 中,器官损害随时间累积,即使在疾病长期存在的情况下也是如此,导致感知到的身心健康受损。充分的免疫抑制治疗,预防疾病发作和尽量减少接触糖皮质激素,对降低损害累积的风险至关重要。